Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Portfolio Pulse from Vandana Singh
Intellia Therapeutics announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002, a CRISPR candidate for hereditary angioedema (HAE). A single dose led to a 95% mean reduction in monthly HAE attack rate. William Blair reiterates its Outperform rating, stating the data supports a competitive profile relative to peers like Ionis Pharmaceuticals' donidalorsen.
June 12, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intellia's NTLA-2002 shows a competitive profile relative to peers like Ionis Pharmaceuticals' donidalorsen, according to William Blair.
While the news highlights the competitive profile of Intellia's NTLA-2002 relative to Ionis Pharmaceuticals' donidalorsen, it does not directly indicate any negative or positive impact on Ionis' stock price in the short term.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Intellia's NTLA-2002 shows promising results in Phase 1 study for HAE treatment, with a 95% mean reduction in attack rate. William Blair reiterates Outperform rating.
The positive interim results from the Phase 1 study of NTLA-2002 indicate a strong efficacy profile for the treatment of HAE. This, combined with William Blair's reiteration of its Outperform rating, is likely to have a positive short-term impact on Intellia's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100